College of Medicine, King Saud University, Riyadh, Saudi Arabia.
J Urol. 2010 Jul;184(1):315-8. doi: 10.1016/j.juro.2010.01.058. Epub 2010 May 20.
We prospectively evaluated the efficacy and durability of combined intradetrusor botulinum-A toxin and endoscopic treatment for vesicoureteral reflux with anal irrigation as a total endoscopic and anal irrigation management approach. This minimally invasive protocol is used to manage myelomeningocele and noncompliant bladder in children who do not respond to standard conservative therapy and have urine and stool incontinence.
Ten females and 3 males with a mean +/- SD age of 5.3 +/- 2.5 years with myelomeningocele and vesicoureteral reflux who did not respond to standard conservative treatment were prospectively included in this study. All had at least 1 year of followup. All patients received a cystoscopic intradetrusor injection of 12 U/kg (maximum 300 U) botulinum-A toxin into an infection-free bladder. Vesicoureteral reflux in a total of 20 refluxing ureters, including bilateral vesicoureteral reflux in 7 patients, showed no resolution on pretreatment voiding cystourethrogram. Thus, we administered a submucosal Deflux injection. Since most patients were still diaper dependent due to stool incontinence, we extended management to include complete bowel rehabilitation with the new Peristeen anal irrigation system to manage stool incontinence.
Mean maximum bladder capacity increased significantly from 75 +/- 35 to 150 +/- 45 ml after 1 month (p <0.02), to 151 +/- 48 after 6 months (p <0.002) and to 136 +/- 32 after 1 year (p <000). Maximum detrusor pressure decreased significantly from 58 +/- 14 to 36 +/- 9 cm H(2)O after 1 month (p <0.001), to 39 +/- 9 after 6 months (p <0.001) and to 38 +/- 6 after 1 year (p = 000). Of 20 refluxing ureters (95%) completely resolved, including 1 after attempt 2, and 1 with grade V vesicoureteral reflux remained unchanged despite 2 attempts. Seven of 8 urinary incontinent patients (87.5%) attained complete dryness between catheterizations and 1 partially improved. Ten of 13 patients achieved stool dryness with anal irrigation 1 to 2 times weekly. Three patients who were stool continent on standard enemas did not require this irrigation system.
This new total endoscopic and anal irrigation management approach is a comprehensive, minimally invasive, safe, simple, effective way to achieve most goals when treating these patients by protecting the upper tract, maintaining the bladder at safe pressure and providing a satisfactory social life with satisfactory urine and stool continence.
我们前瞻性评估了联合膀胱内注射肉毒毒素 A 与内镜治疗在经肛门冲洗治疗伴输尿管反流的膀胱输尿管反流中的疗效和持久性,该方法作为一种总内镜和经肛门冲洗管理方法,用于管理伴有尿液和粪便失禁的对标准保守治疗无反应的脊髓脊膜膨出和顺应性膀胱的患儿。这种微创方案用于治疗伴有输尿管反流的脊髓脊膜膨出患儿,这些患儿对标准保守治疗无反应,且存在尿液和粪便失禁。
本研究前瞻性纳入 10 名女性和 3 名男性患儿,平均年龄为 5.3 ± 2.5 岁,患有脊髓脊膜膨出和伴输尿管反流,对标准保守治疗无反应。所有患儿均接受至少 1 年的随访。所有患儿均在无感染的膀胱内接受 12 U/kg(最大 300 U)肉毒毒素 A 的膀胱内注射。在总共 20 个反流输尿管中,包括 7 例双侧输尿管反流,预处理排尿性膀胱尿道造影显示无反流缓解。因此,我们给予黏膜下 Deflux 注射。由于大多数患儿仍因粪便失禁而依赖尿布,我们将管理扩展至使用新型 Peristeen 经肛门冲洗系统进行完整的肠道康复,以管理粪便失禁。
1 个月后,最大膀胱容量从 75 ± 35 ml 显著增加至 150 ± 45 ml(p <0.02),6 个月后增加至 151 ± 48 ml(p <0.002),1 年后增加至 136 ± 32 ml(p <0.000)。最大逼尿肌压力从 58 ± 14 cm H₂O 显著降低至 36 ± 9 cm H₂O(p <0.001),6 个月后降低至 39 ± 9 cm H₂O(p <0.001),1 年后降低至 38 ± 6 cm H₂O(p = 0.000)。20 个反流输尿管中有 19 个(95%)完全缓解,包括 1 个在第 2 次尝试后缓解,1 个 V 级反流的输尿管无变化,尽管进行了 2 次尝试。8 例尿失禁患儿中,7 例(87.5%)完全达到无导尿间隙期,1 例部分改善。13 例粪便失禁患儿中,10 例通过每周 1-2 次经肛门冲洗达到粪便干燥。3 例接受标准灌肠后保持粪便干燥的患儿不需要这种冲洗系统。
这种新的总内镜和经肛门冲洗管理方法是一种全面、微创、安全、简单、有效的方法,通过保护上尿路、将膀胱维持在安全压力下以及提供令人满意的社会生活和满意的尿便控,来实现治疗这些患者的大多数目标。